Switzerland
🤝 In trade negotiations
Switzerland's trade profile with the United States is dominated by two industries that define Swiss excellence: pharmaceuticals and luxury watches. Novartis and Roche alone account for a significant portion of the $53.2 billion in imports, making Switzerland's per-capita trade deficit with the US one of the largest in the world.
Current Tariff
📊31%
Was 1.2%
US Imports
📥$53.2B
2024 total
US Exports
📤$22.4B
2024 total
Trade Balance
⚖️$-30.8B
US deficit
Trade Flow (2024)
Tariff Rate Change
📈 5-Year Import Trend
📋 Trade Relationship Analysis
Switzerland's trade profile with the United States is dominated by two industries that define Swiss excellence: pharmaceuticals and luxury watches. Novartis and Roche alone account for a significant portion of the $53.2 billion in imports, making Switzerland's per-capita trade deficit with the US one of the largest in the world.
The 31% reciprocal tariff is the highest rate applied to any Western European country, reflecting the magnitude of the $30.8 billion deficit. As a non-EU member, Switzerland must negotiate independently — it cannot rely on Brussels' collective bargaining power, but it also isn't bound by EU retaliation decisions.
Swiss watches face an existential pricing challenge. Rolex, Patek Philippe, Omega, and other luxury watchmakers exported $3.2 billion to the US in 2024. A 31% tariff adds $5,000-$30,000 to a luxury timepiece, potentially pushing buyers toward pre-owned markets or encouraging more purchases during European travel.
Pharmaceuticals represent the bulk of trade value: Novartis and Roche produce cancer treatments, immunology drugs, and other critical medications. Like Ireland, much of this trade reflects the global pharma industry's corporate structure rather than genuine bilateral imbalance. Switzerland has engaged in active negotiations, offering to increase US investment and reduce its own agricultural protections — one of the world's most restrictive farm subsidy regimes.
Tariff Impact
Pre-2025
1.2%
Current
31%
Increase
+29.8%
🏷️ Top Imported Products
| Product | Tariff Rate | Import Value | Price Impact |
|---|---|---|---|
| Pharmaceuticals (Novartis, Roche) | 31% | $28.4B | +12-20% on cancer/biotech drugs |
| Luxury Watches (Rolex, Patek) | 31% | $3.2B | +$5,000-30,000 per watch |
| Medical Instruments & Devices | 31% | $6.8B | +$20K-100K per device |
| Gold & Precious Metals | 31% | $5.4B | +15-20% per ounce (refined) |
| Chocolate (Lindt, Toblerone) | 31% | $480M | +$1-3 per bar |
| Chemicals & Fragrances | 31% | $4.2B | +$15-40 per perfume |
📅 Tariff Timeline
🎯 Retaliation — US Products Targeted
| US Product Targeted | US Exports at Risk | Estimated Loss |
|---|---|---|
| Switzerland negotiating independently (not EU member) | N/A | N/A |
| Potential targets: US agricultural products, machinery | $2.4B | TBD |
💡 Did You Know?
- •Switzerland has the highest per-capita trade deficit with the US of any country — $3,500 per Swiss citizen
- •Rolex alone accounts for over 25% of the global luxury watch market — a 31% tariff reshapes the entire industry
- •Novartis and Roche together account for ~5% of all prescription drugs sold in the United States
- •Swiss chocolate exports to the US have tripled since 2010, led by Lindt's growing American obsession